Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 8Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Infiltrating Bladder Urothelial Carcinoma 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 15Nivolumab 10avelumab 9atezolizumab 8Gemcitabine 8Cisplatin 8Magnetic Resonance Spectroscopy 6durvalumab 5Specimen Handling 5Docetaxel 5Carboplatin 5Paclitaxel 4Ipilimumab 4tislelizumab 3sacituzumab govitecan 3enfortumab vedotin 3Taxes 3Pemetrexed 3Mitomycin 3eribulin 2erdafitinib 2cabozantinib 2Doxorubicin 2CTLA-4 Antigen 2ALT-803 2zimberelimab 1veliparib 1urelumab 1tazemetostat 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Transitional Cell × Cystectomy × Clear all
NCT02968732 2025-07-04

Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder

Fox Chase Cancer Center

Phase NA Active not recruiting
65 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡